BAB 5
KESIMPULAN DAN SARAN

5.1 Kesimpulan

1. Adanya perbedaan signifikan pada aktivitas fagositosis makrofag peritoneal terhadap *latex beads* antara kelompok kontrol negatif, kontrol positif, dan kelompok perlakuan kombinasi Isoniazid-Glukomanan secara *in vitro.*
2. Perbedaan konsentrasi Glukomanan 0,05%, 0,1%, 0,2% dan 0,4% dalam kombinasi Isoniazid-Glukomanan menunjukkan pengaruh yang signifikan terhadap peningkatan aktivitas fagositosis makrofag peritoneal terhadap *latex beads* secara *in vitro.*

5.2 Saran

1. Melakukan studi lebih lanjut terhadap aplikasi efektivitas dari kombinasi Isoniazid-Glukomanan menggunakan bakteri langsung dalam pengembangan terapi TB serta mengevaluasi keamanannya.
2. Studi molekuler terhadap jalur aktivasi makrofag terkait ekspresi gen TLR, dan sitokin proinflamasi (TNF-α, IL-1β, dan IL-6) untuk menginformasi mekanisme imunomodulasi glukomanan dalam meningkatkan aktivitas fagositosisi.

DAFTAR PUSTAKA

Ahalwat, S., Bhatt, D.C., Rohilla, S., Jogpal, V., Sharma, K., Virmani, T., Kumar, G., Alhalmi, A., Alqahtani, A.S., Noman, O.M. and Almoiliqy, M. (2023). Mannose-Functionalized Isoniazid-Loaded Nanostructured Lipid Carriers for Pulmonary Delivery: In Vitro Prospects and In Vivo Therapeutic Efficacy Assessment, *Pharmaceuticals*, **16(8)**.

Alsayed, S.S.R. and Gunosewoyo, H. (2023). Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets, *International Journal of Molecular Sciences*, **24(6)**.

Akilbekova, D., Philiph, R., Graham, A., and Bratlie, K. M. (2014). Macrophage Reprogramming: Influence of Latex Beads with Various Functional Groups on Macrophage Phenotype and Phagocytic Uptake In Vitro. *Journal of Biomedical Materials Research*, **(103) 1**.

Bekale, R.B., Du Plessis, S.M., Hsu, N.J., Sharma, J.R., Sampson, S.L., Jacobs, M., Meyer, M., Morse, G.D. and Dube, A. (2019). Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines, *Pharmaceutical Research*, **36(1)**.

Biraro, I.A., Egesa, M., Kimuda, S., Smith, S.G., Toulza, F., Levin, J., Joloba, M., Katamba, A., Cose, S., Dockrell, H.M., and Elliott, A.M. (2015). Effect if Isoniazid Preventive Therapy on Immune Responses to *Mycobacterium tuberculosis* : an Open Label Randomised, Controlled, Exploratory Study, *BMC Infectious Diseases*, **15(438)**.

Bogan, K.L. and Brenner, C. (2013). Biochemistry: Niacin/NAD(P), *Encyclopedia of Biological Chemistry*, 2nd ed., pp. 172–178.

Buckner, C.A., Lafrenie, R.M., Dénommée, J.A., Caswell, J.M., Want, D.A., Gan, G.G., Leong, Y.C., Bee, P.C., Chin, E., Teh, A.K.H., Picco, S., Villegas, L., Tonelli, F., Merlo, M., Rigau, J., Diaz, D., Masuelli, M., Korrapati, S., Kurra, P., Puttugunta, S., Picco, S., Villegas, L., Tonelli, F., Merlo, M., Rigau, J., Diaz, D., Masuelli, M., Tascilar, M., de Jong, F.A., Verweij, J. and Mathijssen, R.H.J. (2016). 'Regulation of Phagocytosis in Macrophages', in Poloamina.

Victory Ibigo's *Textbook of Phagocytosis-Main Key of Immune System*, IntechOpen **11**, p. 13.

Cao, B., Li, Q., Huang, Z., Huang, X., Zhu, Y., Xiao, K., Huang, F. and Zhong, L. (2020). Influence of Isoniazid on T Lymphocytes, Cytokines, and Macrophages in Rats, *Brazilian Journal of Pharmaceutical Sciences*, **56**, pp. 1–9.

CDC. (2019). Self-study modules on tuberculosis, *Clinics in Chest Medicine* [Preprint]. Available at: https://www.cdc.gov/tb/education/ssmodules/default.htm.

Chandra, P., Grigsby, S.J. and Philips, J.A. (2022). Immune evasion and provocation by Mycobacterium tuberculosis, *Nature Reviews Microbiology*, **20(12),** pp. 750–766.

Chisholm, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., and DiPiro, J. T. (2016). Diseases of Infectious Origin. In *Pharmacotherapy Principles & Practice* (4th ef., pp. 1123-113). McGraw-Hill Education.

Dai, J., Chen, J., Qi, J., Ding, M., Liu, W., Shao, T., Han, J. and Wang, G. (2021). Konjac Glucomannan from Amorphophallus Konjac Enhances Immunocompetence of the Cyclophosphamide-Induced Immunosuppressed Mice, *Food Science and Nutrition*, **9(2)**, pp. 728–735.

Dao, L., Chen, S., Sun, X., Pang, W., Zhang, H., Liao, J., Yan, J. and Pang, J. (2023). Construction and sustained release of konjac glucomannan/naringin composite gel spheres, *Frontiers in Nutrition*, **9 (1)**, pp. 1–11.

DiPiro, J. T., Yee, G. C., Posey, L. M., Haines, S. T., Nolin, T. D., and Ellingrod, V. (2020). *Pharmacotheraphy : A Pathopysiologic Approach*.

du Sert, N.P., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S.T., Howells, D.W., Hurst, V., Karp, N.A., Lazic, S.E., Lidster, K., MacCallum, C.J., Macleod, M., Pearl, E.J., Petersen, O.H., Rawle, F., Reynolds, P., Rooney, K., Sena, E.S., Silberberg, S.D., Steckler, T. and Würbel, H. (2020). Reporting animal research: Explanation and elaboration for the arrive guidelines 2.0, *PLoS Biology*.

Ehrt, S., Schnappinger, D. and Rhee, K.Y. (2018). Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis, *Nature Reviews Microbiology*, **16(8)**, pp. 496–507.

Espinosa-Pereiro, J., Sánchez-Montalvá, A., Aznar, M.L. and Espiau, M. (2022). MDR Tuberculosis Treatment, *Medicina (Lithuania)*, **58(2)**, pp. 1–34.

Flannagan, R.S., Jaumouille, V and Grinstein, S. (2012). The Cell Biology of Phagocytosis, *Annual Review of Pathology*, **7**, pp. 61-98.

González-González, J.S., Martínez-Santiago, A.M.M., Martínez-Martínez, F.J., Emparán-Legaspi, M.J., Pineda-Contreras, A., Flores-Alamo, M. and García-Ortega, H. (2020). Cocrystals of isoniazid with polyphenols: Mechanochemical synthesis and molecular structure, *Crystals*, **10(7)**, pp. 1–14.

Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H. and Cheng, Q. (2025). Tissue macrophages: origin, heterogeneity, biological functions, diseases and therapeutic targets, *Signal Transduction and Targeted Therapy*, **10(1)**.

Hirayama, D., Iida, T. and Nakase, H. (2018). The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis, *International Journal of Molecular Sciences*, **19(1)**.

Isbaniah, F., Burhan, E., Sinaga, B. Y., Behtri, D., Yanifitri, Handayani, D., Harsini, Agustin, H., Artika, I. N., Aphridasari, J., Lasmaria, R., Russilawati, Soedarsono, and Sugiri, Y. J. R. (2021). *Tuberculosis : Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Perhimpunan Dokter Paru Indonesia.

Khan, S.R., Manialawy, Y. and Siraki, A.G. (2019). Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action, *British Journal of Pharmacology*, **176(24)**, pp. 4599–4608.

Katzung, B. G. (2018). *Basic & Clinical Pharmacology* , 14th ed. McGraw-Hill Education.

Kementrian Kesehatan Republik Indonesia. (2020). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*. Jakarta: Kementrian Kesehatan Republik Indonesia.

Kementrian Kesehatan. (2024). *Peringatan Hari Tuberkulosis Sedunia 2024: Gerakan Indonesia Akhiri Tuberkulosis (GIAT)*, diakses pada 23

Mei 2024, https://tbindonesia.or.id/peringatan-hari-tuberkulosis-sedunia-2024- gerakan-indonesia-akhiri-tuberkulosis-giat/.

Khairani, D., Ilyas, S., and Yurnadi. (2024). *Prinsip dan Praktik Hewan Percobaan Mencit (Mus musculus).* USU Press.

Korolenko, T.A., Bgatova, N.P., Vetvicka, V., 2019. Glucan and Mannan—Two Peas in a Pod. *International Journal of Molecular Sciences* ***20*****(13)**, 3189.

Lale Ngema, S., Dookie, N., Perumal, R., Nandlal, L., Naicker, N., Peter Letsoalo, M., O'Donnell, M., Khan, A., Padayatchi, N. and Naidoo, K. (2023). Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance, *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **33(1)**, p. 100387.

Li, J.Y., Sun, F., Zhou, H.F., Yang, J., Huang, C. and Fan, H. (2019). A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan, *Frontiers in Pharmacology*, pp. 1–9.

Liebenberg, D., Gordhan, B.G. and Kana, B.D. (2022). Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management, *Frontiers in Cellular and Infection Microbiology*, **12(1)**, pp. 1–18.

Maison, D.P. (2022). Tuberculosis pathophysiology and anti-VEGF intervention, *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **27(1)**.

de Martino, M., Lodi, L., Galli, L. and Chiappini, E. (2019). Immune Response to Mycobacterium tuberculosis: A Narrative Review, *Frontiers in Pediatrics*, **7(8)**, pp. 1–8.

Mi, J., Wu, X. and Liang. J., (2024). The advances in Adjuvant Therapy for Tuberculosis with Immunoregulatory Compounds, *Frontiers in Microbiology*, **15(13)**.

Migliori, G.B., Ong, C.W.M., Petrone, L., D'ambrosio, L., Centis, R. and Goletti, D. (2021). The definition of tuberculosis infection based on the spectrum of tuberculosis disease, *Breathe*, **17(3)**, pp. 1–12.

Murphy, K. and Weaver, C. (2017). *Janeway'S Immunobiology*, 9th ed., Garland Science : New York.

Nieto, L.M., Mehaffy, C., Creissen, E., Troudt, J., Troy, A., Ohmann, H.B., Burgos, M., Izzo, A., and Dobos, K.M., (2016). Virulence on

Mycobacterium tuberculosis After Acquisition of Isoniazid Resistance: Individual Nature of *katG* Mutans and the Possible Role of AhpC, *Journal PloS ONE*, **11(11).**

Nugroho, R. A. (2018). *Mengenal Mencit Sebagai Hewan Laboratorium*. Edisi Pertama, Samarinda: Mulawarman University Pers.

Novita, B.D., Wasiyastuti, W., Tjahjono, Y., Wijaya, H., Hadinugroho, W., Wijaya, S., Soegianto, L., Theodora, I., Widoretno, E.T.W., Samsudin, K. and Julian, A. (2024). Glucomannan is a promising isoniazid's enhancer that inducing macrophage phagocytosis, *Journal of Advanced Pharmaceutical Technology and Research*, **15(3)**, pp. 237–241.

Pandey, A. kumar, Bajpai, A., Baboo, V. and Dwivedi, A. (2014). Structural, Electronic, and Vibrational Properties of Isoniazid and Its Derivative N-Cyclopentylidene Pyridine-4-carbohydrazide: A Quantum Chemical Study, *Journal of Theoretical Chemistry*, pp. 1–15.

Paurević, M., Šrajer Gajdošik, M., Ribić, R., (2024). Mannose Ligands for Mannose Receptor Targeting. *International Journal of Molecular Sciences **25***, pp. 1370.

Rahman, F., (2024), Characterizing the Immune Response to *Mycobacterium tuberculosis*: a Comprehnsive Narrative Review and Implications in Disease Relapse, *Frontiers in Immunology*, **15**.

Rybicka, J.M., Balce, D.R., Khan, M.F., Krohn, R.M. and Yates, R.M. (2010). NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the lumenal redox environment of phagosomes, *Proceedings of the National Academy of Sciences of the United States of America*, **107(23)**, pp. 10496–10501.

Salari, N., Kanjoori, A.H., Hosseinian-Far, A., Hasheminezhad, R., Mansouri, K. and Mohammadi, M. (2023). Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis, *Infectious Diseases of Poverty*, **12(1)**, pp. 1–12.

Sankar, J., Chauhan, A., Singh, R. and Mahajan, D. (2024). Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement, *Frontiers in Pharmacology*, **15(9)**, pp. 1–20.

Silva, D.R., Muñoz-Torrico, M., Duarte, R., Galvão, T., Bonini, E.H., Arbex, F.F., Arbex, M.A., Augusto, V.M., Rabahi, M.F. and Mello, F.C. de Q. (2018). Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs, *Jornal Brasileiro de Pneumologia*, **44(2)**, pp. 145–152.

Spoladori, A., Correia, G.F., Castro, I.M. De, Henrique, P., Borges, G., Silva-rodrigues, G., Tavares, E.R., Yamauchi, L.M., Pelisson, M., Regina, M., Perugini, E. and Yamada-ogata, S.F. (2024). Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches, *Diseases*, **12(202)**, pp. 1–24.

Sun, Y., Xu, X., Zhang, Q., Zhang, D., Xie, X., Zhou, H., Wu, Z., Liu, R. and Pang, J. (2023). Review of Konjac Glucomannan Structure, Properties, Gelation Mechanism, and Application in Medical Biology, *Polymers*, **15(8)**.

Susilawati, T.N. and Larasati, R. (2019). A recent update of the diagnostic methods for tuberculosis and their applicability in indonesia: A narrative review, *Medical Journal of Indonesia*, **28(3)**, pp. 284–291.

Tehrani, M.K., Yazdi, M.H. and Pourmand, M.R. (2023). Glucomannan enhanced the macrophage activity in exposure to methicillin-resistant Staphylococcus aureus (MRSA): in-vitro study, *Iranian Journal of Microbiology*, **15(4)**, pp. 557–564.

Ting, K.K.Y., Jongstra-Bilen, J. and Cybulsky, M.I. (2023). The multi-faceted role of NADPH in regulating inflammation in activated myeloid cells, *Frontiers in Immunology*, **14(1)**, pp. 1–8.

Uribe-Quero, E. and Rosales, C. (2017). Control of phagocytosis by microbial pathogens, *Frontiers in Immunology*, **8(10)**, pp. 1–23.

Uribe-Querol, E. and Rosales, C. (2020). Phagocytosis: Our Current Understanding of a Universal Biological Process, *Frontiers in Immunology*, **11(6)**, pp. 1–13.

Vilchèze, C., & Jacobs, W. R. (2014). Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis. Microbiology Spectrum, **2(4)**.

Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T. and Castegna, A. (2019). The metabolic signature of macrophage responses, *Frontiers in Immunology*, **10(2)**, pp. 1–16.

Wang, K., Deng, Y., Cui, X., Chen, M., Ou, Y., Li, D, Guo, M., Li, W.

(2023). PatA Regulates Isoniazid Resistance by Mediating Mycolic Acid Synthesis and Controls Biofilm Formation by Affecting Lipid Synthesis in Mycobacteria, *American Society for Microbiology*, Microbiology Spectrum: **11(3)**, p. 1-12.

Wesnawa, M.A.D.P. and Kusmiati, T. (2020). Drug Induced Hepatitis pada Tuberkulosis Paru dengan Multisite Tuberkulosis Ekstraparu, *Jurnal Respirasi*, **5(2),** p. 34.

WHO. (2024). *Global TBC Report 2024*. Diakses pada 10 Januari 2024, https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.